Nutex Health Reports Strong 2025 Results, 82% Revenue Growth, and Announces $25M Share Repurchase
NUTX sits 75% above its 52-week low of $40.67 on elevated volume (2.2× avg).
Summary
Nutex Health Inc. announced robust full-year 2025 financial results, including an 82.4% revenue increase and a 152.6% Adjusted EBITDA surge, alongside the remediation of material weaknesses and a new $25 million share repurchase program.
Key Events · Earnings and Guidance · NUTX
-
Strong Full-Year 2025 Financial Performance
Total revenue increased 82.4% to $875.3 million for 2025, with net income attributable to Nutex Health rising to $70.8 million from $52.1 million in 2024. Adjusted EBITDA surged 152.6% to $259.6 million.
-
Significant Cash Generation and Balance Sheet Strength
The company reported net cash from operating activities of $248.1 million for 2025, and cash and cash equivalents increased to $185.6 million as of December 31, 2025, up from $40.6 million in 2024.
-
Remediation of Material Weaknesses
Nutex Health successfully remediated all previously disclosed material weaknesses in internal controls over financial reporting during 2025, enhancing transparency and investor confidence.
-
New $25 Million Share Repurchase Program
The Board of Directors authorized a second stock repurchase program of up to $25.0 million of common stock over the next six months, aimed at increasing shareholder value and offsetting future dilution from stock compensation.
Analysis · NUTX · Trade & Services
Nutex Health Inc. reported exceptionally strong full-year 2025 financial results, with significant growth across key metrics including an 82.4% increase in total revenue and a 152.6% rise in Adjusted EBITDA. The company also generated substantial cash from operations and significantly boosted its cash reserves. A notable positive is the remediation of all previously disclosed material weaknesses in internal controls, enhancing investor confidence. While fourth-quarter reported revenue and Adjusted EBITDA showed declines, these were attributed to one-time arbitration claim adjustments and timing, with underlying adjusted revenue showing an increase. The announcement of a new $25 million share repurchase program, representing a substantial portion of the company's market capitalization, signals management's confidence and commitment to shareholder value.
At the time of this filing, NUTX was trading at $71.34 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $745M. The 52-week trading range was $40.67 to $193.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.